Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Subscribe To Our Newsletter & Stay Updated
